Identifying urine markers to predict responses to immunotherapy in kidney cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with metastatic renal cell carcinoma (mRCC) who are about to receive immuno-oncology (IO) therapies. Participants will provide fresh urine samples for analysis using advanced metabolomics and proteomics techniques to identify biomarkers that can predict treatment efficacy and potential side effects. The study aims to enhance personalized treatment approaches by understanding how these urinary markers correlate with patient responses to therapy. It is a multi-center, single-arm study that does not involve any direct interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 20 years
2. Subjects diagnosed as advanced or metastatic renal cell carcinoma (a/mRCC)
3. Subjects who are about to receive IO-based therapy
4. ECOG performance 0, 1, 2, and 3
5. Life expectancy \>3 months
6. eGFR \> 15 ml/min/1.73 m2 (Stage IV Chronic Kidney Disease or better)
7. Willing to sign the informed consent form

Exclusion Criteria:

1. Subjects NOT willing to sign the informed consent form
2. Subjects with active infection or active urinary tract infection, as shown by urinary WBC \> 5/HPF
3. Subjects having co-existing other malignancies that need active treatment. Those subjects with other malignancies that do not need active treatment are allowed to join the study.
4. Subjects taking any immune-modulating agents, including but not limited to corticosteroid, immune-suppressants, etc. at the discretion of recruiting investigators
5. Subjects who have taken any IO-based therapy before.
6. Subjects who have received other systemic anti-cancer therapies within 4 weeks of screening are not allowed. However, subjects who had a washout period of the above agents for \>4 weeks are allowed to enroll. Subjects who have received or are receiving targeted therapy are allowed to join the study.

Where it's running

• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Study coordinator: Yeong Shiau Pu, MD PhD
• Email: pu5249@ntuh.gov.tw
• Phone: 886-2-23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• PF-08634404 alone and with other anticancer medicines for adults with advanced kidney cancer.

  This tests whether PF-08634404, given alone or with other cancer medicines, is safe and helps adults with locally advanced or metastatic kidney cancer who have not had prior systemic treatment.

  Recruiting at 157 sites Phase 1/2 Pfizer · Phoenix, Arizona and 182 other locations · NCT07227415

• Combining sasanlimab, palbociclib, and axitinib for metastatic kidney cancer

  This test tries a combination of sasanlimab, palbociclib, and axitinib in people with advanced or metastatic clear cell or translocation renal cell carcinoma to see if it works and is safe.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07123090

• Zanzalintinib with a bone-strengthening agent for metastatic clear cell RCC with bone metastases

  This phase 2 trial tests zanzalintinib plus a bone-strengthening agent in adults with metastatic clear cell renal cell cancer that has spread to bone and progressed after 1–3 prior therapies, including IO therapy.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT07043608

• Digital symptom monitoring for people starting cabozantinib plus nivolumab for advanced clear-cell kidney cancer

  This project tests whether weekly digital self-reports of symptoms can help guide treatment management for adults beginning cabozantinib plus nivolumab for advanced clear-cell kidney cancer during the first three months.

  Recruiting at 3 sites Phase 4 Centre Francois Baclesse · Annecy and 18 other locations · NCT07028125

• Combination of XL092 and Immunotherapy for Advanced Clear Cell Kidney Cancer

  This study is testing if a new drug called XL092, alone or with another treatment called nivolumab, can help people with advanced clear cell kidney cancer who haven't responded well to previous therapies.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · La Jolla, California and 4 other locations · NCT06863311

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.